Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 5/20 | 0.68 |
| ▸ | ESR1 | P03372 | 9/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | PGR | P06401 | 4/20 | 0.65 |
| ▸ | AR | P10275 | 4/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.65 |
| ▸ | SNCA | P37840 | 3/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.65 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.63 |
| ▸ | STS | P08842 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5680184 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL5681898 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL6258554 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL5679650 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL6255675 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL14116626 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL3357076 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL5678022 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL6256154 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL5677831 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270845-A1 | 16-Hydroxyestratrienes as selectively active estrogens | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-11-30 | — | — | US | claimed |
| US-7109360-B1 | 16-hydroxyestratrienes as selectively active estrogens | SCHERING AG (DE) | 2006-09-19 | — | — | US | claimed |
| EP-1144431-B1 | 16-HYDROXYESTRATRIENES AS SELECTIVE ESTROGENS | SCHERING AG (DE) | 2005-12-21 | — | — | EP | claimed |
| US-20040053898-A1 | Combination preparation with a erbeta selective estrogen and serm or antiestorgen | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-03-18 | — | — | US | claimed |
| US-7414043-B2 | 9-α-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2008-08-19 | — | — | US | disclosed |
| US-20080182829-A1 | 8Beta-Hydrocarbyl-Substituted Estratrienes As Selectively Active Estrogens | PETERS OLAF | 2008-07-31 | — | — | US | disclosed |
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | KOSEMUND DIRK | 2008-06-05 | — | — | US | disclosed |
| US-7378404-B2 | 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-05-27 | — | — | US | disclosed |
| US-20060270845-A1 | 16-Hydroxyestratrienes as selectively active estrogens | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-11-30 | — | — | US | disclosed |
| US-7109360-B1 | 16-hydroxyestratrienes as selectively active estrogens | SCHERING AG (DE) | 2006-09-19 | — | — | US | disclosed |
| EP-1580192-A2 | 16-Hydroxyestratrienes as selective estrogens | Schering AG (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20030171345-A1 | 8Beta-substituted 11beta-aryl-estra-1,3,5,(10)-triene derivatives | SCHERING AG (DE) | 2003-09-11 | — | — | US | disclosed |
| US-20030130249-A1 | Therapeutic use of estrogen receptor (ER)beta-selective agonists for triggering somatotropic, organotropic and anticatabolic effects (somatotropic therapy) | SCHERING AG (DE) | 2003-07-10 | — | — | US | disclosed |
| US-6190691-B1 | ADMINISTERING FORMULATION COMPRISING TUMOR NERCOSIS FACTOR (TNF) PRODUCTION-INHIBITORY AMOUNT OF A COMPOUND SELECTED FROM LOPERAMIDE AND DIPHENOXYLATE TO MAMMAL | ADOLOR CORPORATION | 2001-02-20 | — | — | US | disclosed |
| US-5962477-A | USING LOPERAMIDE | ADOLOR CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0937460-A2 | Use of an antidiarrheal for the manufacture of a medicament for the treatment of inflammatory conditions | Adolor Corporation (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0757558-A4 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORP (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0757558-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995027510-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270845-A1 | 16-Hydroxyestratrienes as selectively active estrogens | ESR1, ESR2, ESRRA | SHBG 7/4885ESR1 1/4885ESR2 2/4885 |
| US-20080182829-A1 | 8Beta-Hydrocarbyl-Substituted Estratrienes As Selectively Active Estrogens | ESR2, ESR1, ESRRA | SHBG 10/4885ESR1 2/4885ESR2 1/4885 |
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | ESRRA, ESR2, ESR1 | SHBG 12/4885ESR1 3/4885ESR2 2/4885 |
| US-20030171345-A1 | 8Beta-substituted 11beta-aryl-estra-1,3,5,(10)-triene derivatives | CYP19A1, HSD17B11, GPER1 | SHBG 19/4885ESR1 10/4885ESR2 4/4885 |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | ESRRA, ESR2, HSD17B11 | SHBG 12/4885ESR1 7/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.